June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Comparison of the surgical outcomes of ab interno trabeculotomy using Tanito microhook, suture, and Trabectome
Author Affiliations & Notes
  • Chunxiao Sun
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Hanako Ohashi Ikeda
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Tomoko Hasegawa
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Shogo Numa
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Kenji Suda
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Masahiro Miyake
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Takanori Kameda
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Akitaka Tsujikawa
    Kyoto Daigaku Daigakuin Igaku Kenkyuka Igakubu, Kyoto, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Chunxiao Sun None; Hanako Ikeda Alcon Japan, Kyoto Drug Discovery & Development, Code F (Financial Support), Santen Pharmaceutical, Novartis Pharma, Senju Pharmaceutical, Alcon Pharma, Eisai, Code R (Recipient); Tomoko Hasegawa None; Shogo Numa Senju Pharmaceutical, Code R (Recipient); Kenji Suda Alcon Japan, Code F (Financial Support), Santen Pharmaceutical, Senju Pharmaceutical, Kowa Pharmaceutical, Otsuka Pharmaceutical, Novartis Pharma, Code R (Recipient); Masahiro Miyake Novartis Pharma, Code F (Financial Support), Bayer Yakuhin, Kowa Pharmaceutical, Alcon Japan, HOYA, Novartis Pharma, AMO Japan, Santen Pharmaceutical, Senju Pharmaceutical, Johnson & Johnson K.K., Code R (Recipient); Takanori Kameda Alcon Japan, Code F (Financial Support), Alcon Japan, AMO Japan, Senju Pharmaceutical, Santen Pharmaceutical, Code R (Recipient); Akitaka Tsujikawa Senju Pharmaceutical, Bayer Yakuhin, Novartis Pharma, HOYA, Ellex, MSD, Allegan Japan, Eisai, Daiich-Sankyo, Chugai Pharmaceutical, Code C (Consultant/Contractor), Canon, Findex, Santen Pharmaceutical, Kowa Pharmaceutical, Pfizer, AMO Japan, Senju Pharmaceutical, Wakamoto Pharmaceutical, Alcon Japan, Novartis Pharma, Otsuka Pharmaceutical, Bayer Yakuhin, Nitten Pharmaceutical, Code F (Financial Support), Bayer Yakuhin, Senju Pharmaceutical, Novartis Pharma, Santen Pharmaceutical, Alcon Pharma, AbbVie GK, AMO Japan, Kowa Pharmaceutical, Wakamoto Pharmaceutical, Code R (Recipient)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3688 – A0373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chunxiao Sun, Hanako Ohashi Ikeda, Tomoko Hasegawa, Shogo Numa, Kenji Suda, Masahiro Miyake, Takanori Kameda, Akitaka Tsujikawa; Comparison of the surgical outcomes of ab interno trabeculotomy using Tanito microhook, suture, and Trabectome. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3688 – A0373.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study compared the clinical outcomes between ab interno trabeculotomy using Tanito microhook (TMH), suture (sLOT), and Trabectome (TOM) and explored the most beneficial trabecular meshwork (TM) incision range.

Methods : A retrospective analysis of pre- and postoperative (up to 60 months) intraocular pressure (IOP), glaucoma medications, and complications was performed for patients with primary open angle glaucoma who underwent cataract extraction combined with ab interno trabeculotomy using TMH, sLOT, or TOM at Kyoto University Hospital between January 2016 and June 2021.

Results : The mean preoperative IOP was 18.8±4.4, 18.8±6.7 and 17.1±6.1 mmHg in TMH (58 eyes), sLOT (69 eyes), and TOM (29 eyes) groups, respectively (P=0.37). The mean IOP value and IOP reduction% were similar at all the study time points. The mean IOP was 13.6±2.3, 14.1±3.5, and 12.9±2.8 mmHg (P=0.19), and IOP reduction% was 24.7±18.6, 18.8±23.8, and 21.0±18.0 % (P=0.31) in TMH, sLOT, and TOM groups at postoperative 3-moth follow-up. IOP spike and hyphema occurred most often in the sLOT group (27.5%, 26.1%), followed by the TOM group (13.8%, 17.2%), and the least in TMH group (6.9%, 6.9%). In all three groups, patients with spike or hyphema did not undergo wider degrees of incision but achieved similar IOP reduction when compared with those without spike or hyphema. The use of anticoagulant and antiplatelet did not increase the risk of hyphema in each group. A correlation between TM incision degrees and IOP reduction was only found in the TMH group (P=0.0014) and not in the sLOT (P=0.31) and TOM (P=0.41) groups. After mixing all the data and reclassifying them by incision degrees into 1- to 4-quadrant groups, we found that the 2-quadrant group had the least incidence of hyphema (P=0.26) and spike (P=0.02), while the 3-quadrant group had the greatest IOP reduction% (P=0.02). Consistently, TM incision degree was a predicator of postoperative IOP reduction% in multiple linear regression analysis of patients within 270 degrees’ incision (P=0.0002).

Conclusions : TMH, sLOT, and TOM trabeculotomy provided comparable IOP reduction efficacies, while hyphema and IOP spike were more frequent in the sLOT group. Hyphema and IOP spike did not result from wider TM incision degrees. Incision of 90–180° had the least incidence of complications, while a 180–270° incision conferred the greatest IOP reduction.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×